Waters Raises Every 2026 Target As Adjusted Profit Climbs 21% To $4.10 A Share

The instrument maker's reported earnings fell to $0.82 a share on Becton Dickinson deal charges, but it lifted its full-year revenue outlook by $43 million.

Share
Waters Raises Every 2026 Target As Adjusted Profit Climbs 21% To $4.10 A Share

Waters, which makes liquid chromatography and mass spectrometry instruments for pharmaceutical, industrial and academic labs, raised every piece of its 2026 outlook after adjusted third-quarter earnings of $4.10 a share topped its own guidance, the company said in an 8-K filed Tuesday. Earnings under standard accounting fell to $0.82 a share from $2.50 a year earlier.

Adjusted profit up, reported profit down

Third-quarter revenue was $1.767 billion, $14 million above the midpoint of Waters' guidance. Organic revenue, which excludes the acquired businesses, was $871 million, up 9% as reported and 10% in constant currency from $800 million a year earlier.

Adjusted earnings per share rose 21% from $3.40. Net income fell to $81 million from $149 million, which the company attributed to purchase accounting charges, acquisition costs and restructuring costs tied to the Becton Dickinson deal.

Purchased-intangibles amortization was $244 million in the quarter, against $12 million a year earlier. Intangible assets stood at $8.275 billion on October 3, up from $558 million at the end of 2025, and goodwill at $9.369 billion from $1.340 billion.

Biggest division and the acquired businesses

The Analytical Sciences Division, the former core Waters business, posted revenue of $703 million, up 8% as reported and 9% in constant currency. Instrument revenue rose 9% as reported and 10% in constant currency, and chemistry consumables rose 10% as reported and 12% in constant currency.

The Biosciences and Diagnostic Solutions businesses bought from Becton Dickinson contributed $896 million, against $885 million on a comparable prior-year basis. CEO Udit Batra said integration and synergy work is "ahead of schedule." Debt stood at $5.133 billion, up from $1.407 billion at the end of 2025.

Waters also said it has bought MOBILion Systems, whose ion-mobility technology separates molecules by size, shape and charge. The company expects it to broaden its entry into proteomics.

The new 2026 guidance

Waters now expects full-year revenue of $6.479 billion to $6.497 billion, a $43 million increase at the midpoint, and adjusted earnings per share of $14.60 to $14.70.

For the fourth quarter it guides to revenue of $1.801 billion to $1.819 billion and adjusted EPS of $4.58 to $4.68.

Management said it would lay out its starting 2027 growth framework, covering reshoring, synergies and AI-related demand, on its 8:00 a.m. ET call Tuesday.

Sources